Premium
A case of granulomatosis with polyangiitis and pyoderma gangrenosum successfully treated with infliximab and rituximab
Author(s) -
Donmez Salim,
Pamuk Omer N.,
Gedik Mustafa,
Ak Recep,
Bulut Gulay
Publication year - 2014
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12274
Subject(s) - medicine , pyoderma gangrenosum , rituximab , infliximab , granulomatosis with polyangiitis , dermatology , refractory (planetary science) , azathioprine , pathergy , vasculitis , surgery , disease , lymphoma , physics , astrobiology
Here, we present a young male patient who was admitted with alveolar hemorrhage, arthritis and cutaneous lesions, who later developed bilateral orbital involvement and pyoderma gangrenosum ( PG ). He also had pathergy test positivity. The patient was refractory to conventional immunosuppressive therapy. Therefore, multiple devastating PG lesions and disease activity in granulomatosis with polyangiitis ( GPA ) were controlled with infliximab. Later, rituximab was used with success to prevent recurrence of symptoms. The relationship of PG with various autoimmune diseases is known; however, PG in GPA has been only rarely reported. Biologic agents might prove to be effective in GPA and PG patients who are refractory to standard immunosuppressive therapy.